VAERS Explorer
Back to explore

Report #2896483

Received May 29, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
26 yrs
State
FL
Recovered
Unknown
Vaccinated
Apr 15, 2026
Onset
Feb 1, 2026
Days to onset
Hospital days

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
IPVPOLIO VIRUS, INACT. (IPOL)SANOFI PASTEURN/AY1D03P1SC / RA
IPVPOLIO VIRUS, INACT. (IPOL)SANOFI PASTEURUNKY1D03P1SC / RA

Symptoms (2)

Product storage issueNo adverse event

Symptom narrative

Temperature excursion for punctured IPOL with maximum /Lowest Temperature reached: 46.8ºF Duration:1 hour and 10 minutes/ products administered post excursion, with no reported adverse event; Initial information received on 14-May-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 26-year-old female patient who was administered with suspect IPV (VERO) [IPOL] post excursion with maximum/lowest temperature reached: 46.8 degree F duration: 1 hour and 10 minutes/products administered post excursion, with no reported adverse event. The patient's past medical history, past drugs, vaccination(s), family history, and concomitant medications were not provided. Concomitant medication(s) included influenza vaccine inact sAg 3v (Flucelvax) and varicella zoster vaccine live (Oka/Merck) (Varivax). On 15-Apr-2026, the patient received 0.5 ml of suspect IPV (VERO) [IPOL] suspension for injection (Strength = standard) frequency: once via subcutaneous route in right arm for immunization, post excursion as exposed with maximum/lowest temperature reached: 46.8 degree F duration: 1 hour and 10 minutes/products administered post excursion, with no reported adverse event (Product storage error) (batch: Y1D03P1, expiry date: 31-Aug-2027). It was reported "human error was involved A pharmacist reported that his intern had initially reported a temperature excursion involving a punctured and unopened inactivated polio vaccine (IPV), while he was calling back because punctured IPV was administered to 3 patients. He reported that the first excursion happened in Feb-2026 involving a punctured and unopened IPV, while the second excursion occurred on 08-May-2026 involving unopened IPV only. The pharmacist asked if the 3 patients needed to be revaccinated. No previous excursion. The patient experienced a temperature excursion for punctured IPV reason: door was left slightly The emergency room/doctor visit and date were unknown to the healthcare professional (HCP). The extended stability data did not cover the excursion". Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Medical history

Comments: NONE

Other medications

Flucelvax; Varivax